Dave Tudor

Chief Executive Officer, Digital Technologies Group

"Dave brings over two decades of international experience in pharmaceutical manufacturing and supply chain strategy. During his 20+ year tenure at GSK, he held several senior leadership positions, including Vice President of Primary Supply chain and Vice President of Manufacturing Strategy.

Following his time at GSK, Dave served as Managing Director of the Medicines Manufacturing Innovation Centre at CPI, where he led initiatives to accelerate innovation and collaboration across the industry.

He now serves as Chief Executive Officer of Digital Technologies Group (DTG), where he continues to advance innovation in pharmaceutical manufacturing through digital transformation and strategic leadership."

Emilie Louvet

Director of Digital for Regulatory Affairs, AstraZeneca

Emilie Louvet is Director of Digital for Regulatory Affairs at AstraZeneca. She has been with AstraZeneca for 9 years holding a variety of roles with focus in generating insights from data; digital transformation and implementing AI solutions for drug development, clinical trial design and now regulatory.

Emilie has a MSc and PhD in Molecular and Cell Biology from Paris 5 University and Institut Jacques Monod (France), and an MBA in Business Management from the PowerMBA. Prior to moving to the industry, Emilie led her research at the Karolinska Institute (Sweden) and at Kyoto University (Japan). She then came back to Europe as head of digital pathology group at Gustave Roussy (France).

Claire MacLeod

Grand Challenge Lead, CPI

Claire graduated with an MEng in Chemical Engineering and went on to complete a PhD on the topic of heterogeneous catalysis for Biodiesel production. She then spent 13 years working in various process development roles at AstraZeneca including specialisations in filtration and continuous processing. From there, Claire moved to CPI’s Medicines Manufacturing Innovation Centre where she is now the Oligonucleotides Grand Challenge Lead, managing a portfolio of projects including Grand Challenge 3 – Sustainable and Scalable Oligonucleotide Manufacturing. 

Natacha Agabalyan

Associate Lead Scientist, Cell and Gene Therapy Catapult

Natacha joined the CGT Catapult in 2018 and brings over a decade of experience in cell and gene therapy development across academia and industry. She gained her PhD in regenerative medicine at Brighton and Sussex Medical School (UK), after which she pursued an academic career focused on the translation of pre-clinical models into cell therapy products. Since joining CGT Catapult, Natacha has focused on leading projects within the Cell Delivery and Digitalisation and Automation programs. This includes internally funded efforts to establish capabilities, develop platform processes, and drive innovation, as well as collaborative projects evaluating, transferring, supporting and developing novel therapies, products and technologies. She has a passion for supporting therapy and technology developers, from product, process and analytical development, evaluation of processes and technologies, understanding regulatory and CMC challenges and utilising digitalisation to drive the industry forwards. 

Sam Whitmarsh

Director of Analytical Science and Digital Transformation, CatSci

Sam Whitmarsh is Director of Analytical Science and Digital Transformation at CatSci, bringing over 20 years of R&D experience from AstraZeneca, BP, and CatSci. After completing a PhD at the University of Bristol, he joined AstraZeneca specialising in analytical science, before establishing BP’s UK mass spectrometry facility and leading its Global Analytical Science Network.

Joining CatSci in 2020, Sam now heads the company’s Analytical business unit, driving innovation and delivery for customers while leading CatSci’s digital transformation strategy – integrating high-throughput experimentation, data analytics, and AI-driven predictive tools across development. He is also founder of LabLinks, a digital platform enabling connected laboratory workflows and data orchestration across the scientific sector. A Fellow of the Royal Society of Chemistry, Sam serves on the Separation Science Interest Group and is a passionate advocate for the role of digital and analytical science in accelerating innovation.